Telix Pharmaceuticals Limited (ASX:TLX)
14.74
+0.10 (0.65%)
Apr 20, 2026, 3:59 PM AEST
Telix Pharmaceuticals Revenue
In the year 2025, Telix Pharmaceuticals had annual revenue of $803.79M USD with 55.61% growth. Telix Pharmaceuticals had revenue of $413.44M in the half year ending December 31, 2025, with 122.47% growth.
Revenue
$803.79M
Revenue Growth
+66.17%
P/S Ratio
4.12
Revenue / Employee
$678.88K
Employees
1,184
Market Cap
4.96B AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 803.79M | 287.24M | 55.61% |
| Dec 31, 2024 | 516.55M | 183.57M | 55.13% |
| Dec 31, 2023 | 332.98M | 224.03M | 205.64% |
| Dec 31, 2022 | 108.95M | 103.42M | 1,873.25% |
| Dec 31, 2021 | 5.52M | 1.51M | 37.53% |
| Dec 31, 2020 | 4.01M | 1.57M | 64.21% |
| Dec 31, 2019 | 2.44M | 2.31M | 1,680.89% |
| Dec 31, 2018 | 137.28K | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.10B |
| Mesoblast | 98.02M |
| Clinuvel Pharmaceuticals | 96.30M |
| Neuren Pharmaceuticals | 64.65M |
| PYC Therapeutics | 20.56M |
| Starpharma Holdings | 14.58M |
| Clarity Pharmaceuticals | 10.58M |
| Orthocell | 9.33M |
Telix Pharmaceuticals News
- 5 days ago - Telix Pharma Doses First Patient In Phase 3 IPAX BrIGHT Trial Of TLX101-Tx; Prices $600 Mln Bonds - Nasdaq
- 5 days ago - Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma - GlobeNewsWire
- 6 days ago - Fundies feast on Telix Pharmaceuticals block amid $US550m convertible - The Australian Financial Review
- 7 days ago - Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs - Benzinga
- 7 days ago - Regeneron (REGN) Partners with Telix Pharmaceuticals - GuruFocus
- 7 days ago - Regeneron (REGN) Partners with Telix Pharmaceuticals for Innovative Radiopharmaceuticals - GuruFocus
- 7 days ago - Regeneron Pharma Partners Telix Pharma To Jointly Develop Radiopharmaceutical Therapies - Nasdaq
- 7 days ago - Telix and Regeneron Announce Strategic Radiopharma Collaboration - GlobeNewsWire